logo
Plus   Neg
Share
Email

Alexion Pharma Announces FDA Approval Of ULTOMIRIS

Alexion Pharmaceuticals, Inc. (ALXN), on Friday, announced the U.S. FDA approved ULTOMIRIS for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells. The approval comes ahead of the PDUFA date of February 18, 2019, set by the FDA as part of an expedited eight month review.

The company noted that regulatory authorities in the EU and Japan are reviewing applications for the approval of ULTOMIRIS as a treatment for adults with paroxysmal nocturnal hemoglobinuria.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tech giant Apple Inc. (AAPL) is reportedly planning to begin assembling a new low-cost iPhone 9 in February. According to Bloomberg, the Cupertino, California-based company is expected to officially unveil the new phone as early as March. The assembly work for the new handset will be split among Taiwan-based... A Louisville, Kentucky-based franchise of Wendy's and Fazoli's restaurants, was ordered by the federal government to pay a civil penalty of $157,114 for violating child labor laws. The U.S. Department of Labor's Wage and Hour Division or WHD said its investigation found that Manna Inc. violated child labor requirements of the Fair Labor Standards Act at 99 Wendy's and Fazoli's restaurants. Tesla's market capitalization briefly crept up the $100 billion mark in extended trading on Tuesday, making it the first publicly-listed automaker in the U.S. to achieve the feat. Tesla's stock gained 7.2 percent to close Tuesday's regular trading session at $547.20, and rose to $555 in after-hours trading, pushing the luxury electric car maker's market valuation to more than $100 billion.
Follow RTT
>